کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
1221248 1494653 2013 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis
موضوعات مرتبط
مهندسی و علوم پایه شیمی شیمی آنالیزی یا شیمی تجزیه
پیش نمایش صفحه اول مقاله
Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis
چکیده انگلیسی


• Identification of different production sites for the protein erythropoietin (EPO).
• Separating EPO glyco isoforms by lectin (WGA) affinity chromatography.
• Measuring the distribution with highly sensitive EPO immunoassay.
• Comparing selected ratios for healthy population and for patients receiving rhEPO.
• Three EPO populations were found: kidney EPO (normal), liver EPO and rhEPO.

The primary production site of erythropoietin (EPO) is shifted from the liver to the kidney shortly after birth. Under conditions of lost or reduced kidney production, it is valuable to measure the production capacity of the liver. However, there is a lack of urine or serum based methods that can distinguish endogenous EPO produced in different cell types. Here is presented a method based on chromatographic interaction with the lectin wheat germ agglutinin (WGA) that can distinguish presumably liver-produced EPO, found in anaemic patients receiving epoetin and darbepoetin, from kidney-produced EPO found in healthy individuals.All the tested samples from haemodialysis patients with end-stage renal disease showed a presence of liver EPO. In some samples, the liver-produced EPO made up 90–100% of total EPO at a concentration of 8–10 ng/L in urine, which indicates that the liver has a quite high production capacity, although not adequate for the degree of anaemia.This glycoform analysis has made it possible to affirm that some anaemic patients can increase their liver-production of EPO. The use of such a method can give better insight into the regulation of non-renal endogenous EPO production, a potential source of EPO intended to replace administration of exogenous EPO.

Figure optionsDownload as PowerPoint slide

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Pharmaceutical and Biomedical Analysis - Volumes 81–82, July–August 2013, Pages 187–192
نویسندگان
, , , ,